Differences among western European countries in anticoagulation management of atrial fibrillation

Summary

Due to improved implementation of guidelines, new scoring approaches to improve risk categorisation, and introduction of novel oral anticoagulants, medical management of patients with atrial fibrillation (AF) is continuously improving. The PREFER in AF registry enrolled 7,243 consecutive patients with ECG-confirmed AF in seven European countries in 2012–2013 (mean age: 71.5 ± 10.7 years; 60.1% males; mean CHA₂DS ₂ -VASc score: 3.4). While patient characteristics were generally homogeneous across countries, anticoagulation management showed important differences: the proportion of patients taking vitamin K antagonists (VKAs) varied between 86.0% (in France) and 71.4% (in Italy). Warfarin was used predominantly in the UK and Italy (74.9% and 62.0%, respectively), phenprocoumon in Germany (74.1%), acenocoumarol in Spain (67.3%), and fluindione in France (61.8 %). The major sites for international normalised ratio (INR) measurements were biology laboratories in France anticoagulation clinics in Italy, Spain, and the UK, and physicians’ offices or self-measurement in Germany. Temporary VKA discontinuation and bridging with other anticoagulants was frequent (at least once in the previous 12 months for 22.9% of the patients, on average; ranging from 29.7% in Germany to 14.9% in the UK). Time in therapeutic range (TTR), defined as at least two of the last three available INR values between 2.0–3.0 prior to enrolment, ranged from 70.3% in Spain to 81.4% in Germany. TTR was constantly overestimated by physicians. While the type and half-lives of VKA as well as the mode of INR surveillance differed, overall quality of anticoagulation management by TTR was relatively homogenous in AF patients across countries.

Keywords

Registry - cross-sectional - anticoagulation - vitamin K antagonists - anticoagulation quality - INR

• References

• 1 Go AS, Mozaffarian D, Roger VL. et al. Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association. Circulation 2013; 127: e6-e245.
• 2 Ohlmeier C, Mikolajczyk R, Haverkamp W. et al. Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace 2013; 15: 1436-1444.
• 3 Albertsen IE, Rasmussen LH, Overvad TF. et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 2013; 44: 1329-1336.
• 4 Hart RG, Pearce LA. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009; 40: 2607-2610.
• 5 Nieuwlaat R, Capucci A, Camm AJ. et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
• 6 Nabauer M, Gerth A, Limbourg T. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
• 7 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
• 8 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 9 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
• 10 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
• 11 Kirchhof P, Ammentorp B, Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation. Primary results of the PREFER in AF Registry. Europace 2014; 16: 6-14.
• 12 Blomstrom-Lundqvist C, Scheinman MM, Aliot EM. et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108: 1871-1909.
• 13 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: e149-246.
• 14 Camm A, Lip G, Atar D. et al. 2012 Focused Update of the ESC Guidelines on the Management of Atrial Fibrillation. Eur Heart J 2012; 33: 2719-2747.
• 15 Bonnemeier H, Bosch RF, Kohlhaussen A. et al. Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Curr Med Res Opin 2011; 27: 995-1003.
• 16 Meinertz T, Kirch W, Rosin L. et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100: 897-905.
• 17 Le Heuzey J, Breithardt G, Camm J. et al. The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation. Am J Cardiol 2010; 105: 687-693.
• 18 Kakkar AK, Mueller I, Bassand JP. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 08: e63479.
• 19 Kakkar AK, Mueller I, Bassand JP. et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163: 13-19. e1.
• 20 Lip GY, Laroche C, Dan GA. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EuroObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319.
• 21 Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000; 14: 339-353.
• 22 Lind M, Fahlen M, Kosiborod M. et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 2012; 129: 32-35.
• 23 Nieuwlaat R, Connolly BJ, Hubers LM. et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res 2012; 129: 715-719.
• 24 Morgan CL, McEwan P, Tukiendorf A. et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
• 25 Lip GY, Frison L, Halperin JL. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
• 26 Witt DM, Delate T, Clark NP. et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res 2013; 132: e124-130.
• 27 Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25: 61-66.
• 28 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
• 29 Connolly SJ, Pogue J, Eikelboom J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
• 30 Van Spall HG, Wallentin L, Yusuf S. et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centres and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012; 126: 2309-2316.
• 31 Labeit AM, Klotsche J, Pieper L. et al. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One 2012; 07: e52229.
• 32 Schaefer JR, Gitt AK, Sonntag F. et al. Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Vasc Health Risk Manag 2013; 09: 71-80.
• 33 Yelland LN, Gialamas A, Laurence CO. et al. Assessing agreement between point of care and pathology laboratory results for INR: experiences from the Point of Care Testing in General Practice Trial. Pathology 2010; 42: 155-159.
• 34 Stavelin A, Meijer P, Kitchen D. et al. External quality assessment of point-of-care International Normalized Ratio (INR) testing in Europe. Clin Chem Lab Med 2012; 50: 81-88.
• 35 Siegal D, Yudin J, Kaatz S. et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639.
• 36 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326S-50S.
• 37 Heidbuchel H, Verhamme P, Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
• 38 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
• 39 van Walraven C, Hart RG, Connolly S. et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410-1416.
• 40 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 41 Shireman TI, Mahnken JD, Howard PA. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130: 1390-1396.
• 42 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 43 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
• 44 Bernard A, Fauchier L, Pellegrin C. et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013; 110: 560-568.
• 45 Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-641.
• 46 Kirchhof P, Nabauer M, Gerth A. et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: 1010-1023.